Rocket Pharmaceuticals, Inc.
RCKT· Nasdaq
Released Aug 5, 2024, after the close
10-Q filed Aug 6, 2024, 37 days after period end · 0000950170-24-091838
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$69.65M | -$65.70M | -$54.40M | -$34.53M |
| EPS Diluted |
Rocket Pharmaceuticals, Inc. · CIK 1281895 · Engraved from SEC EDGAR
| -$0.74 |
| -$0.82 |
| -$0.83 |
| -$0.55 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.